Status:
COMPLETED
Efficacy of Irinotecan and Capecitabine Versus(vs) Cisplatin and Capecitabine in Patients With Esophago-Gastric Cancer
Lead Sponsor:
Johannes Gutenberg University Mainz
Conditions:
Gastric Cancer
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine which Arm (capecitabine + irinotecan versus capecitabine + cisplatin) shows higher response rates in the treatment of advanced gastric-oesophagal cancer Furt...
Detailed Description
capecitabine + irinotecan versus capecitabine + cisplatin, as published by Kang et al. (ASCO 2006)
Eligibility Criteria
Inclusion
- gastric or gastric-oesophagal junction adenocarcinoma
- unidimensional measurable disease
- Karnofsky index \>/=60%
Exclusion
- prior chemo- or radiotherapy
- colorectal diseases
- brain metastases
Key Trial Info
Start Date :
October 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2007
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT00675194
Start Date
October 1 2003
End Date
October 1 2007
Last Update
May 20 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Johannes Gutenberg Universität , I. Medizinische Klinik und Polokilinik
Mainz, Germany, 55101